Trending: Elizabeth Warren takes aim at Amazon’s taxes again during speech at Seattle rally
Seattle Genetics CEO Clay Siegall. (Seattle Genetics photo)

Seattle Genetics on Thursday reported higher-than-expected losses for the fourth quarter, sending shares down 8 percent in after-hours trading.

Quarterly revenues came in at $175 million, above Wall Street expectations and an improvement of 35 percent compared with the same quarter last year.

But losses for the company grew to $120 million, or $0.75 per share, versus analyst estimates of $0.43 per share. The company attributed $53.2 million of the losses to an investment in Immunomedics, a New Jersey-based cancer drugmaker.

Last year, Seattle Genetics’ Adcetris drug won Food and Drug Administration approval for treatment of a fast-growing type of non-Hodgkin lymphoma. It also received approval for a new indication in Canada. Most of the company’s sales come from Adcetris.

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline


Job Listings on GeekWork

Find more jobs on GeekWork. Employers, post a job here.